Medical Condition News

RSS

Sleep quality is poor in soldiers with chronic headaches, find researchers

Some 19 percent of soldiers returning from Iraq have migraine and migraine is suspected in another 17 percent. While prevalence of migraine among the U.S. military is well documented , little is known about sleep quality in soldiers with chronic headaches including post-traumatic headache and migraine.

23 Jun 2010

REM sleep deprivation leads to changes in levels of key proteins that increase risk of migraine: Study

Reporting at the American Headache Society's 52nd Annual Scientific Meeting in Los Angeles this week, new research shows that sleep deprivation leads to changes in the levels of key proteins that facilitate events involved in the underlying pathology of migraine.

23 Jun 2010

BGU researchers develop software program to detect depression in blogs, online texts

Researchers at Ben-Gurion University of the Negev (BGU) developed a software program that can detect depression in blogs and online texts. The software is capable of identifying language that can indicate the writer's psychological state, which could serve as a screening tool.

23 Jun 2010

Phase I/II clinical trials show crizotinib reduces lung cancer tumors

Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.

23 Jun 2010

Superficial relationships lead to feelings of detachment, health-related problems

Hoarding friends on Facebook - or followers on Twitter - won't do much to stave off loneliness if those relationships lack any kind of strong connection, new research finds.

23 Jun 2010

Exercise alone without creatine supplements helps in cardiac rehabilitation

Athletes have been enjoying the benefits of creatine supplements to gain stronger muscles since the 1990s, and the supplement has also proven beneficial among other groups. Could it help cardiac patients regain strength to help with their heart-training workouts as part of rehabilitation? The evidence at this stage suggests not - exercise alone proved a far more powerful tonic for patients in a study out today. The results appear in the journal Clinical Rehabilitation, published by SAGE.

23 Jun 2010

Local health clinics in U.S. do not offer diabetes screening, obesity prevention programs to poor clients: Study

A new nationwide study finds that some local health clinics do not offer diabetes screening or obesity prevention programs to their clients, who tend to be poor. The clinics need to be "armed and equipped" to respond to the growing threat from type 2 diabetes and obesity in the United States, said researcher and study co-author Ann Albright. "These are huge problems that we're facing. We want to be sure that we're responding effectively."

23 Jun 2010

Mice treated with XOMA 052 experiences improvement in measures associated with diabetes: Endocrinology

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the publication of data from a mouse model of diet-induced obesity in the June, 2010 edition of the journal Endocrinology. The data showed that mice treated with XOMA 052 both prophylactically and therapeutically experienced improvement in measures associated with diabetes and cardiovascular disease including reduction in glycosylated hemoglobin levels, improvement in glucose control, improved beta-cell survival and function, and a reduction in total cholesterol without reduction in high density lipoprotein.

23 Jun 2010

Cell>Point submits IND application for Phase 1b/2 99mTc-EC-G diagnostic trial in assessing CAD patients

Cell>Point announced today that it has submitted to the Food and Drug Administration an Investigational New Drug (IND) application for a Phase 1b/2 trial of its 99mTc-EC-G diagnostic in assessing patients with Coronary Artery Disease (CAD).

23 Jun 2010

FDA grants Tolera's TOL101 orphan drug designation for treatment of T1DM

Tolera Therapeutics, Inc., was granted orphan drug status by the United States Food and Drug Administration (FDA) for TOL101 (anti-TCR murine monoclonal antibody, type IgM), for treatment of recent onset immune-mediated Type 1 diabetes mellitus (T1DM). Designation is granted for treatment of patients sixteen years of age and younger with immune-mediated T1DM and preserved pancreatic beta-cell function, commonly referred to as juvenile diabetes.

23 Jun 2010

Genentech's Lucentis for treatment of macular edema following RVO receives FDA approval

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis® (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO). The FDA approved this new indication after a six-month Priority Review.

23 Jun 2010

Nuon study confirms potential utility of tranilast as uricosuric agent

Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that results from clinical and preclinical studies demonstrating the ability of tranilast to reduce serum uric acid levels and monosodium urate crystal-induced inflammation - two important risk factors for gout - were presented at The European League Against Rheumatism (EULAR) 2010 Annual European Congress of Rheumatology in Rome, Italy, June 16-19, 2010.

22 Jun 2010

Ethicon Endo-Surgery renews research collaboration agreement with UC and Metabolic Diseases Institute

Ethicon Endo-Surgery, Inc. (EES) today announced it has renewed its research collaboration agreement with the University of Cincinnati (UC) and its Metabolic Diseases Institute (MDI). The three-year, $13.5M grant extension, is part of the EES Metabolic Applied Research Strategy (MARS), which also includes research from GI Metabolism Laboratory and Weight Center at the Massachusetts General Hospital (MGH).

22 Jun 2010

Affymax's database lock achievement in Phase 3 Hematide trial triggers $30M milestone payment from Takeda

Affymax, Inc. today announced that it has received $30 million in development milestone payments from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize Hematide™/peginesatide, Affymax's investigational drug for the treatment of anemia in chronic renal failure patients.

22 Jun 2010

Neurologix announces positive results from Phase 2 trial of NLX-P101 for advanced PD

Neurologix, Inc., today announced positive results in a Phase 2 trial of its investigational gene therapy for advanced Parkinson's disease, NLX-P101. Study participants who received NLX-P101 experienced statistically significant and clinically meaningful improvements in off-medication motor scores compared to control subjects who received sham surgery.

22 Jun 2010

World's first invisible-in-the-canal hearing aid launched

Starkey Laboratories, Inc., one of the world's leading hearing technology companies, is excited to introduce the S Series™ iQ OtoLens™, the world's first invisible-in-the-canal (IIC) hearing aid. OtoLens, a custom-molded hearing aid built using Starkey's Comfort Fit process, lives in the second bend of the ear, meaning that it is truly 100 percent invisible.

22 Jun 2010

Aesculap Implant Systems introduces S4 MIS Cannulated Pedicle Screw Spine Fusion System

Aesculap Implant Systems, LLC is pleased to announce the launch of the S4® MIS (Minimally Invasive Solutions) Cannulated Pedicle Screw Spine Fusion System.

22 Jun 2010

Teens to call upon Congress to fund drug research for rare diseases

Teens from across the United States whose siblings have cystic fibrosis will press their elected officials in Washington, D.C., June 24, to fund drug research and increase access to clinical trials for those with rare diseases.

22 Jun 2010

Fructose makes cells mature into fat cells in belly fat, study finds

Fructose, the sugar widely used as high-fructose corn syrup in soft drinks and processed foods, often gets some of the blame for the widespread rise in obesity. Now a laboratory study has found that when fructose is present as children's fat cells mature, it makes more of these cells mature into fat cells in belly fat and less able to respond to insulin in both belly fat and fat located below the skin.

22 Jun 2010

Beneficial effects of LifeVantage's Protandim on DMD mouse model published in Journal of Dietary Supplements

LifeVantage Corporation, the maker of Protandim®, a patented, science-based solution to oxidative stress, announced today that a peer-reviewed manuscript was published in the Journal of Dietary Supplements examining the beneficial effects of Protandim® on a mouse model of Duchenne Muscular Dystrophy (DMD), an X-linked inherited disease affecting one in 3,500 males.

22 Jun 2010

Medical Condition News

Sleep quality is poor in soldiers with chronic headaches, find researchers

REM sleep deprivation leads to changes in levels of key proteins that increase risk of migraine: Study

BGU researchers develop software program to detect depression in blogs, online texts

Phase I/II clinical trials show crizotinib reduces lung cancer tumors

Superficial relationships lead to feelings of detachment, health-related problems

Exercise alone without creatine supplements helps in cardiac rehabilitation

Local health clinics in U.S. do not offer diabetes screening, obesity prevention programs to poor clients: Study

Mice treated with XOMA 052 experiences improvement in measures associated with diabetes: Endocrinology

Cell>Point submits IND application for Phase 1b/2 99mTc-EC-G diagnostic trial in assessing CAD patients

FDA grants Tolera's TOL101 orphan drug designation for treatment of T1DM

Genentech's Lucentis for treatment of macular edema following RVO receives FDA approval

Nuon study confirms potential utility of tranilast as uricosuric agent

Ethicon Endo-Surgery renews research collaboration agreement with UC and Metabolic Diseases Institute

Affymax's database lock achievement in Phase 3 Hematide trial triggers $30M milestone payment from Takeda

Neurologix announces positive results from Phase 2 trial of NLX-P101 for advanced PD

World's first invisible-in-the-canal hearing aid launched

Aesculap Implant Systems introduces S4 MIS Cannulated Pedicle Screw Spine Fusion System

Teens to call upon Congress to fund drug research for rare diseases

Fructose makes cells mature into fat cells in belly fat, study finds

Beneficial effects of LifeVantage's Protandim on DMD mouse model published in Journal of Dietary Supplements

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News